The dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor sotagliflozin reduced major adverse cardiovascular events, with significant reductions in the individual outcomes of myocardial ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

A drug already used to treat people who have diabetes and/or chronic kidney disease could have added heart disease benefits, ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and ...

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into ...

Preoperative use of SGLT2 inhibitors among patients with type 2 ... (Jardiance), ertugliflozin (Steglatro), and the dual SGLT1/2 inhibitor sotagliflozin (Inpefa) -- should withhold their ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Updated ...

Reports Q4 revenue $$26.55M, consensus $6.48M.Cash and Investments: As of December 31 , Lexicon (LXRX) had $238M in cash and short-term ...

Neither of the selective SGLT2 inhibitors have yet been shown to reduce MI and stroke events. Sotagliflozin, however, inhibits SGLT2 as well as gastrointestinal SGLT1; the latter effect, the study ...

Michael Broukhim, MD “I would like to see more data differentiating the actions of a SGLT2 inhibitor and an agent that inhibits both SGLT1 and SGLT2, including some comparative effectiveness ...

In parallel, we continue to build strong differentiating evidence for sotagliflozin, an SGLT1/2 inhibitor, and we are continuing to enroll a Phase 3 clinical trial in support of a potential broad ...